NERANDOMILAST

Information current as at: 1 July 2026

PBAC meeting date: November 2026

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Jascayd®
Form and strength:: Tablet 9 mg

Tablet 18 mg
Submission sponsor:: BOEHRINGER INGELHEIM PTY LTD
Condition/indication: (therapeutic use): Idiopathic pulmonary fibrosis (IPF)
Listing requested:: To request listing of nerandomilast for the treatment of patients with IPF who: - are treatment-naïve and initiate nerandomilast as their first pharmacological therapy; - have discontinued nintedanib or pirfenidone due to intolerance, adverse events, or disease progression, and who subsequently receive nerandomilast as monotherapy; and - receive nerandomilast in combination with nintedanib or pirfenidone.
Funding program:: PBS General Schedule
Request authority level:: Authority Required (Telephone/Online)
PBAC Submission type:: New PBS listing (–)
Comment:: --
Other PBAC consideration:: --

Submission received for:: November 2026 PBAC meeting
2Opportunity for consumer comment:: Open 22/07/2026 and close 16/09/2026 (see PBS Website)
3PBAC meeting:: Has not yet occurred
4PBAC outcome published:: Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

a1294

Page last updated

23 July 2026

v.9.19